Literature DB >> 24180484

Systematic evaluation of non-inferiority and equivalence randomized trials of anti-infective drugs.

Yunfei Li1, Yingchun He, Yucheng Sheng, Kun Wang, Jingjing Wang, Jihan Huang, Juan Yang, Qingshan Zheng.   

Abstract

The non-inferiority (NI) and equivalence (EQ) design is used widely in the clinical trials of anti-infective drugs, but still many arguments for, and against, conducting active control NI/EQ trials rather than simple placebo controlled trials. We searched Pubmed database and conducted a systematic literature review (1992-2011) to assess the methodological aspects of NI and EQ randomized trials of anti-infective drugs. A total of 335 publications with 337 trials were included. Of them, 235 trials reported a pre-specified margin of 10-15%. A proportion (e.g., cure, successful, failure) was used as the primary outcome in 316 trials (93.8%). Test treatments were non-inferior or equivalent to the control treatment in 325 trials (93.4%). The historical evidence for the effect of the control drug was specified in 38 trials (11.3%). For the literature of NI/EQ trials in anti-infective treatment, aspects that need improvement include the description of study participation, trial implementation, historical evidence and endpoint for the efficacy of control, inclusion of flow diagrams and figures that present margins and confidence intervals according to CONSORT criteria.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24180484     DOI: 10.1586/14787210.2013.851600

Source DB:  PubMed          Journal:  Expert Rev Anti Infect Ther        ISSN: 1478-7210            Impact factor:   5.091


  5 in total

1.  Informed Consent to Study Purpose in Randomized Clinical Trials of Antibiotics, 1991 Through 2011.

Authors:  Peter Doshi; Peter Hur; Mark Jones; Husam Albarmawi; Tom Jefferson; Daniel J Morgan; Patricia A Spears; John H Powers
Journal:  JAMA Intern Med       Date:  2017-10-01       Impact factor: 21.873

2.  Comment: Fundamentals and Innovation in Antibiotic Trials.

Authors:  Scott R Evans; Dean Follmann
Journal:  Stat Biopharm Res       Date:  2015-12-17       Impact factor: 1.452

3.  Desirability of Outcome Ranking (DOOR) and Response Adjusted for Duration of Antibiotic Risk (RADAR).

Authors:  Scott R Evans; Daniel Rubin; Dean Follmann; Gene Pennello; W Charles Huskins; John H Powers; David Schoenfeld; Christy Chuang-Stein; Sara E Cosgrove; Vance G Fowler; Ebbing Lautenbach; Henry F Chambers
Journal:  Clin Infect Dis       Date:  2015-06-25       Impact factor: 9.079

Review 4.  Lipoglycopeptide Antibacterial Agents in Gram-Positive Infections: A Comparative Review.

Authors:  Françoise Van Bambeke
Journal:  Drugs       Date:  2015-12       Impact factor: 9.546

5.  Daptomycin dosing in obese patients: analysis of the use of adjusted body weight versus actual body weight.

Authors:  Ashley N Fox; Winter J Smith; Katherine E Kupiec; Stephanie J Harding; Beth H Resman-Targoff; Stephen B Neely; Bryan P White; Ryan E Owens
Journal:  Ther Adv Infect Dis       Date:  2019-01-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.